DFMO tested as follow-up treatment for medulloblastoma

Official title: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on .

The short version

This trial is testing a drug called DFMO in people with a brain tumor called medulloblastoma.

Read our full plain-language summary

What the trial team says

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number
NCT04696029
Stage of testing
Phase 2
Conditions studied
Medulloblastoma

Where it is running

This trial lists 26 sites.

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.